Journal article
131I-tositumomab in lymphoma
Abstract
Radioimmunoconjugates are radioisotope-bound monoclonal antibodies that target radiation specifically to sites of lymphoma involvement. Initial studies of 131I-tositumomab in non-Hodgkin lymphoma (NHL) have suggested benefit in patients with relapsed or refractory indolent disease. However, the routine adoption of this agent is tempered by concerns about associated toxicities and unclear long-term benefit. Based on a comprehensive search for …
Authors
Cheung MC; MacEachern JA; Haynes AE; Meyer RM; Imrie K
Journal
Current Oncology, Vol. 16, No. 5, pp. 32–47
Publication Date
January 1, 2009